Management of Newly Diagnosed Multiple Myeloma Today, and in the Future

Strategies combining novel agents (anti-CD38 monoclonal antibodies, immunomodulators, and proteasome inhibitors) as triplets and quadruplets are the current standard of care frontline treatment for both TI and TE myeloma. These combinations are providing impressive efficacy with manageable toxicity and will continue to be further optimized in the coming years. ASCT continues to be the standard of care for all fit patients until there is evidence of superior outcomes with alternative approaches. While most patients are benefitting from the current treatment paradigm, outcomes for highrisk MM continue to lag behind and there is an urgent need to develop novel approaches for these patients. In the future, potent T-cell-redirecting therapies, including CAR -T and bispecific antibodies, could potentially revolutionize the treatment of ND MM.